Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa

NCT00571584 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00571584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00571584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2002
Completion date
March 31, 2004
Enrollment
24 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a with inhibitors, haemophilia b with inhibitors